Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03785756 · ClinicalTrials.gov registry record · Phase 3
Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars
A Phase 3 study, sponsored by Reckitt Benckiser Healthcare (UK) Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
NCT03785756 is a Phase 3 study that has completed, run by Reckitt Benckiser Healthcare (UK) Limited. The registered enrollment target is 280 participants.
The verdict
NCT03785756, a Phase 3 study, has completed, sponsored by Reckitt Benckiser Healthcare (UK) Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
Study Summary
This is a single centre, randomised, double-blind, double-dummy, parallel group, multiple-dose, active and placebo-controlled efficacy study to evaluate the efficacy and safety of 2×300mg ibuprofen Prolonged Release (PR) tablets in subjects with postoperative dental pain.
Interventions
- DRUG Ibuprofen 300 mg Oral Tablet
- DRUG Ibuprofen 200 mg Oral Tablet
- DRUG Placebo of PR tablet
- DRUG Placebo of IR tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2019-04-29 |
| Est. Completion | 2020-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03785756
The ClinicalTrials.gov registry entry for NCT03785756 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser Healthcare (UK) Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ibuprofen 300 mg Oral Tablet is the first listed.
NCT03785756 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03785756 about?
NCT03785756 is a clinical study titled "Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars". This is a single centre, randomised, double-blind, double-dummy, parallel group, multiple-dose, active and placebo-controlled efficacy study to evaluate the efficacy and safety of 2×300mg ibuprofen Prolonged Release (PR) tablets in subjects with postoperative dental pain.
What is the current status of trial NCT03785756?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2019-04-29. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT03785756?
The interventions under investigation include: Ibuprofen 300 mg Oral Tablet (DRUG), Ibuprofen 200 mg Oral Tablet (DRUG), Placebo of PR tablet (DRUG), Placebo of IR tablet (DRUG).
Who is sponsoring clinical trial NCT03785756?
This trial is sponsored by Reckitt Benckiser Healthcare (UK) Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.